The role of aromatase inhibitors in the treatment of metastatic breast cancer

Seminars in Oncology

Volumn 30, Issue 4 SUPPL. 14, 2003, Pages 33-45

  Mouridsen, Henning ^a   Gershanovich, Michael ^b  

^a Rigshospitalet   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; CORTICOSTEROID; EXEMESTANE; FADROZOLE; FORMESTANE; GESTAGEN; LETROZOLE; MEGESTROL ACETATE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; VOROZOLE;

ALGORITHM; BREAST CANCER; BREAST METASTASIS; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0141762741     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00301-4     Document Type: Article

References (31)

1. Pyrhonen S, Ellmen J, Vuorinen J, et al: Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 56:133-143, 1999
2. Solomayer EF, Diel IJ, Meyberg GC, et al: Metastatic breast cancer: Clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59:271-278, 2000
3. Dorssers LC, Van der Flier S, Brinkman A, et al: Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 61:1721-1733, 2001
4. Goss PE, Strasser K: Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19:881-894, 2001
5. Brueggemeier RW: Aromatase, aromatase inhibitors, and breast cancer. Am J Ther 8:333-344, 2001
6. Gradishar WJ, Jordan VC: Hormonal therapy for breast cancer. An update. Hematol Oncol Clin North Am 13:435-455, 1999
7. Roseman BJ, Buzdar AU, Singletary SE: Use of aromatase inhibitors in postmenopausal women with advanced breast cancer. J Surg Oncol 66:215-220, 1997
8. Santen RJ, Worgul TJ, Samojlik E, et al: A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305:545-551, 1981
9. Smith IE, Harris AL, Morgan M, et al: Tamoxifen versus aminoglutethimide in advanced breast carcinoma: A randomized cross-over trial. BMJ 283:1432-1434, 1981
10. Trunet PF, Mueller P, Girard F, et al: The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects. J Clin Endocrinol Metab 74:571-576, 1992
11. Dowsett M, Smithers D, Moore J, et al: Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer. Eur J Cancer 30A:1453-1458, 1994
12. Goss PE, Winer EP, Tannock IF, et al: Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. J Clin Oncol 17:52-63, 1999
13. Gershanovich M, Chaudri HA, Campos D, et al: Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 9:639-645, 1998
14. Dombemowsky P, Smith I, Falkson G, et al: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461, 1998
15. Buzdar A, Douma J, Davidson N, et al: Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 19:3357-3366, 2001
16. Buzdar AU, Jones SE, Vogel CL, et al: A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 79:730-739, 1997
17. Jonat W, Howell A, Blomqvist C, et al: A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A:404-412, 1996
18. Buzdar A, Jonat W, Howell A, et al: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 14:2000-2011, 1996
19. Buzdar AU, Jonat W, Howell A, et al: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 83:1142-1152, 1998
20. Rose C, Vtoraya O, Pluzanska A, et al: Letrozole (Femara) vs. anastrozole (Arimidex): Second-line treatment in postmenopausal women with advanced breast cancer. Proc Am Soc Clin Oncol 21:34a, 2002 (abstr 131)
21. Kaufmann M, Bajetta E, Dirix LY, et al: Exemestane is superior to megestrol acetate after tamoxifen failure in post-menopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 18:1399-1411, 2000
22. Lonning PE, Bajetta E, Murray R, et al: Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial. J Clin Oncol 18:2234-2244, 2000
23. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001
24. Mouridsen H, Gershanovich M, Sun Y, et al: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101-2109, 2003
25. Nabholtz JM, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18:3758-3767, 2000
26. Bonneterre J, Thurlimann B, Robertson JF, et al: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18:3748-3757, 2000
27. Bonneterre J, Buzdar A, Nabholtz JM, et al: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92:2247-2258, 2001
28. Dirix LY, Piccart MJ, Lohrisch C, et al: Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): A European Organisation for the Research and Treatment of Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn. Proc Am Soc Clin Oncol 20:29a, 2001 (abstr 114)
29. Howell A, Mackintosh J, Jones M, et al: The definition of the "no change" category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 24:1567-1572, 1988
30. Robertson JF, Williams MR, Todd J, et al: Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 25:469-475, 1989
31. Robertson J, Willsher P, Cheung K, et al: The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer 33:1774-1779, 1997